Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD
Objective: To assess efficacy, safety, and tolerability of multiple doses of pridopidine in HD patients (pts) with signs of motor dysfunction. Background: Prior trials suggested…Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis
Objective: To compare the proportion of subjects on polypharmacy after five years in the deep brain stimulation (DBS) in early stage Parkinson’s disease (PD) pilot…Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil
Objective: To evaluate the therapeutic potential of the Rho Kinase (ROCK) inhibitor Fasudil in translational models of Parkinson’s disease (PD). Background: There is still a…Medical Treatment Termination in Parkinson’s Disease Patients after Hepad Therapy: A Case Series
Objective: To report seven clinical cases of treatment completion and improvement of symptoms after a PD therapy regimen that included Hepad. Background: DOPA decarboxylase inhibitor…The influence of neurorehabilitation on Parkinson medication
Objective: To investigate the influence of neurorehabilitation on the dose changes of Parkinson medication over time. Background: In progressive disorders such as Parkinson’s disease (PD),…Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease.
Objective: Objective: In order to improve the understanding of the alpha-synuclein system and its role in Parkinson’s disease, Elan and Rosa collaborated in the development…Parkinson’s Disease Medications Availability in Each Philippine Region
Objective: This study aimed to enumerate the different Parkinson’s disease medications in the Philippines and describe the distribution and availability among the 17 regions of…Determinant factors of treatment adherence in Parkinson’s disease
Objective: To determine factors predicting treatment adherence in patients with idiopathic Parkinson’s disease. Background: Parkinson’s disease is the second most common cause of neurodegenerative disease…Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience
Objective: To review the benefits and complications of ILI for PD in a tertiary movement disorders center in Canada. Background: ILI has been in use…Clinical Experience with Initiation of Carbidopa/Levodopa Enteral Suspension in Parkinson’s Disease Patients with Cognitive Impairment
Objective: To assess the safety and efficacy of carbidopa/levodopa enteral suspension (CLES) in Parkinson’s disease (PD) patients with cognitive impairment. Background: As Parkinson’s Disease progresses,…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 34
- Next Page »